CorNova(R) Receives CE Mark Approval for Valecor Platinum(R) Coronary Stent System
Advanced Platinum Surface Maximizes Biocompatibility and Biostabilityin a Bare-Metal Stent
BURLINGTON, Mass., June 23 /PRNewswire/ -- CorNova Inc. today announced that it has received CE mark approval for its Valecor Platinum Coronary Stent
Newest Coated Stent Does Well in Real-World Trial
Safe and effective in an 'all-comer population,' researchers say
WEDNESDAY, June 17 (HealthDay News) -- The newest drug-coated stent
has performed well in a real-life trial, Dutch cardiologists report.
The Xience stent
-- a flexible metal-mesh tube coated with the drug everolimus --...
Broncus Technologies' Exhale Stent and Other New Devices to Prompt Robust Growth In Emphysema Treatment Market, According to Millennium Research Group
WALTHAM, Mass., June 16 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the rise in the US prevalence of emphysema is prompting device firms to develop endoscopic devices used to diagnose or treat the condition. Curre...
XTENT, Inc. Receives Conditional Approval for Investigational Device Exemption of Custom NX(R) Drug Eluting Stent System from United States Food and Drug Administration
MENLO PARK, Calif., June 4 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT ) today announced that the Company received conditional approval from the United States Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) authorizing it to begin its pivotal clinical pro...
Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study
Safety and Efficacy Rates in Patients with Challenging Anatomy Consistent with Superior Results from Randomized Clinical Trials
BARCELONA, Spain, May 21 /PRNewswire-FirstCall/ -- New data presented today at EuroPCR from an international, post-approval, single-arm study show that Abbott's mark...
SYNTAX Substudy Shows Positive Outcomes for Left Main Patients Treated With TAXUS(R) Express2(R) Stent System
NATICK, Mass. and BARCELONA, Spain, May 19 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced positive outcomes from a substudy of patients with left main coronary disease who were treated with the TAXUS(R) Express2(R) Paclitaxel-Eluting Coronary Stent
Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Artery Disease
MOBILITY trial showcases company's leadership in developing innovative endovascular treatment options
ABBOTT PARK, Ill., April 1 /PRNewswire-FirstCall/ -- Abbott ( NYSE: ABT ) today announced the initiation of MOBILITY, a clinical trial studying the safety and efficacy of the Absolute Pro(T...
XTENT Receives CE Mark Approval for CUSTOM NX (R) Drug-Eluting Stent System
60 millimeter Custom NX 60 is the world's longest coronary stent
to ever be approved
MENLO PARK, Calif., March 19 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT ) today announced that it has received CE Mark approval for its CUSTOM NX drug-eluting stent
(DES) System. The CE Mark indic...
Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System
Japanese patients now have access to second-generation drug-eluting stent
NATICK, Mass., March 3 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the launch of its TAXUS(R) Liberte(R) Paclitaxel-Eluting Coronary Stent
System in Japan. The product was app...
Blood Flow Measurement Boosts Stent Outcomes
Technology reduces deaths, complications, but may be too costly for some centers, experts say
WEDNESDAY, Jan. 14 (HealthDay News) -- A sophisticated measure of blood flow to determine where artery-opening stents should be implanted is more effective than the X-ray examinations now comm...
Cardiac stent patients with diabetes may benefit from drug that counteracts the effects of leptin
NEW YORK (Dec. 17, 2008) The naturally high levels of leptin in diabetic patients may reduce the effectiveness of drug-eluting stents used to treat heart blockages, but using a chemical that differs from the one commonly used to coat stents could counteract this effect.
The work by researchers...
Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels
ABBOTT PARK, Ill., Dec. 17 /PRNewswire-FirstCall/ -- Abbott ( NYSE: ABT )
today announced the start of SPIRIT Small Vessel, a clinical trial evaluating
a 2.25 mm size of the XIENCE V(TM) Everolimus Eluting Coronary Stent
The 2.25 mm stent
system would offer physicians an option for treat...
New Type of Stent Shows Promise
It recruits blood vessel cells as a kind of heart-healthy coating, experts explain
TUESDAY, Nov. 11 (HealthDay News) -- A new generation of stents shows promise in avoiding the late-onset problems that have plagued drug-eluting stents in patients with heart disease, researchers say.
MDCT: Non-invasive alternative to bronchoscopy in patients with airway stent complications
Multidetector CT (MDCT) scans are highly accurate in detecting airway stent
complications according to a recent study performed at Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, MA.
MDCT correctly identified 29 (97%) of 30 complications in 21 patients, including all...
Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter
TAXUS(R) Atom(TM) in more than 500 accounts Company opening new PROMUS(TM) accounts
NATICK, Mass., Oct. 14 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX ) today announced estimated U.S. market shares for
September for its two drug-eluting ste...
New Type of Stent Appears Safe, Effective
Artery-opening device emits drug from a biodegradable polymer
MONDAY, Sept. 1 (HealthDay News) -- One of a "new generation" of artery-opening, drug-eluting stents appears equally effective as older models in boosting outcomes for heart patients, a new head-to-head study shows.
How to use endoscopic stent for biliary stricture trauma?
Biliary stricture after blunt abdominal trauma is an extremely rare condition. There is no definitive treatment for a biliary stricture caused by blunt abdominal trauma. Nonsurgical intervention, especially endoscopic treatment has recently been used and has shown promising results.
Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan
Japan Submission Includes Clinical Data Demonstrating Superiority of XIENCE V Compared to TAXUS(R) Drug Eluting Stent
TOKYO, June 2 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) today
announced that it has submitted an application for Seizo Hanbai Shonin
(Marketing Authorization L...
High Growth Potential for Carotid Stent and Thoracic Aortic Stent Graft Markets
Procedural growth could increase by more than 20% over the next five years, according to Millennium Research Group
WALTHAM, Mass., May 20 /PRNewswire/ -- According to Millennium Research
Group's US Markets for Peripheral Vascular (PV) Devices 2008 report, the
thoracic aortic sten...
TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients with Diabetes Compared to Non-Diabetics in ARRIVE Registry Program
NATICK, Mass. and BARCELONA, Spain, May 13 /PRNewswire-FirstCall/ --
Boston Scientific Corporation (NYSE: BSX ) today announced results from an
analysis of nearly 7,500 patients from its TAXUS ARRIVE 1 and 2 registries,
which are designed to confirm the performance of the TAXUS(R) Express2(TM...
New Drug-Coated Stent Does Well in Early Trial
But doctors want more data, and device not yet approved for use in U.S.
TUESDAY, April 22 (HealthDay News) -- A new kind of drug-coated stent
was better at keeping arteries open than an older stent
in the first large-scale U.S. study of the device, researchers report.
"This study su...
Melt-Away Stent Works Well in Trial
Absorbed harmlessly in the body, it could replace traditional metal stents
THURSDAY, March 13 (HealthDay News) -- A polymer stent
that is quietly absorbed by the body after it has done its job of keeping a coronary artery open has worked well in an international trial, researchers repo...
NIH report on intracranial stent points out need for upcoming large-scale clinical trial
LOS ANGELES (Feb. 13, 2008) A preliminary study funded by the National Institutes of Health found that a stent
designed to open clogged arteries in the brain was successfully deployed in nearly all cases and significantly reduced arterial blockage in the short term. But data on the long-term bene...
Half of patients undergoing cerebrovascular stent placement respond poorly to clopidogrel
(CHICAGO) A study by researchers at Rush University Medical Center, published in the February issue of the American Journal of Neuroradiology, finds that half of patients undergoing cerebrovascular stent
placement did not respond well to clopidogrel. Clopidogrel (Plavix) and aspirin are medicatio...
Super-Thin Drug-Free Coating 'Hides' Stent as It Unblocks Heart Arteries
Avoids Deadly Clotting Problems of Drug-Eluting Stents
HOLLYWOOD, Fla., Jan. 21 /PRNewswire/ -- A new stent
with a nanothin
surface application shows promise in opening and healing blocked heart
arteries without the life-threatening dangers of drug-eluting stents,
according to a study...
'Drug-Free' Stent Coating Shows Promise
Trial finds polymer reduces inflammatory reaction associated with current devices
MONDAY, Jan. 21 (HealthDay News) -- A new kind of coated stent
holds promise for overcoming the major problems with these tubes that are inserted to keep arteries open after clot-clearing angioplasty, Ita...
XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
- Company continues U.S. pivotal trial discussions with FDA -
MENLO PARK, Calif., Dec. 27 /PRNewswire-FirstCall/ -- XTENT, Inc.
(Nasdaq: XTNT ), the developer of customizable drug-eluting stent
systems, today announced that it has submitted its application to the
TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients
TAXUS Liberte has more CE Mark-approved indications than any other drug-eluting stent
NATICK, Mass., Dec. 21 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX ) announced today that its TAXUS(R) Liberte(TM)
paclitaxel-eluting coronary stent
Devax Announces Completion of Enrollment of DIVERGE Trial of Novel Drug- Eluting Stent System for Bifurcation Lesions
- Five hundred patients treated with company's AXXESS(TM) System to date -
LAKE FOREST, Calif., Dec. 12 /PRNewswire/ -- Devax, Inc., a medical
device company focused on developing next generation products for
interventional cardiology, today announced that the Company has completed
FDA Advisory Committee Recommends Approval of Abbott's XIENCE(TM) V Drug Eluting Stent System
ABBOTT PARK, Ill., Nov. 29 /PRNewswire-FirstCall/ -- Abbott (NYSE:
ABT)announced today that the Circulatory System Devices Advisory Panel to
the U.S. Food and Drug Administration (FDA) recommended approval for the
XIENCE(TM) V Everolimus Eluting Coronary Stent
System. XIENCE V is a
Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System
NATICK, Mass., Nov. 29 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX ) today welcomed the recommendation of a U.S. Food
and Drug Administration (FDA) advisory panel to approve with conditions the
PROMUS(TM) / XIENCE(TM) V everolimus-eluting coronary stent
LeMaitre Vascular Launches Next-Generation Stent Graft Delivery System
BURLINGTON, Mass., Nov. 16 /PRNewswire-FirstCall/ -- LeMaitre Vascular,
Inc. (Nasdaq: LMAT ) today announced the commercial launch of the TT(TM)
Tortuous Tracker Delivery System, the next-generation introducer for
LeMaitre Vascular's EndoFit(R) and UniFit(TM) Aortic Stent
FDA Approves Boston Scientific's TAXUS(R) Liberte(R) Long Stent
NATICK, Mass., July 16 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS((R)) Liberte((R)) Long Paclitaxel-Eluting Coronary Stent
System, a next-generation d...
AbbeyMoor Medical Receives FDA Approval for Design Improvements to The Spanner(TM) Prostatic Stent
PARKERS PRAIRIE, Minn., July 6 /PRNewswire/ -- AbbeyMoor Medical Inc., a developer and manufacturer of medical devices for the management and treatment of prostatic obstruction, announced today that it has received PMA approval from the US Food and Drug Administration (FDA) for design changes to...
NYC first: Complex aneurysm treated using new fenestrated endograft stent
NEW YORK (July 07, 2008) -- In a New York City metro-area first, a 93-year-old Bronx man underwent implantation of a new stent
graft at NewYork-Presbyterian Hospital, the only center on the Eastern Seaboard with access to this investigational device. The new stent
graft was implanted under an FDA...
Registry unveils 'real-world' data on novel excel stent
CHICAGO, Ill. (March 31, 2008) Real-world use of a novel drug-eluting stent
coated with a biodegradable polymer is associated with good clinical outcomes, according to one-year data from a large international registry. Results of the CREATE study, which focused on the sirolimus-eluting Excel sten...
Spirit II explores long-term performance of XIENCE V stent
CHICAGO, Ill. (March 31, 2008) Early results of the SPIRIT II study showed that the XIENCE V stent
was superior to the Taxus stent
in six-month findings on angiography and trended better on one-year clinical outcomes. Now, a new analysis shows that after two years, the investigational everolimus-...
The Lancet publishes first clinical trial data of a fully bioabsorbable drug-eluting stent
ABBOTT PARK, Ill., March 13, 2008 Data published today in The Lancet from ABSORB, the worlds first clinical trial of a fully bioabsorbable drug eluting stent
for the treatment of coronary artery disease, demonstrated no stent
thrombosis, no clinically driven target lesion revascularizations (re-t...
Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
New 2.25 mm Diameter Stent
Now Available in Europe, Asia and Latin America
ABBOTT PARK, Ill., March 11 /PRNewswire-FirstCall/ -- Abbott (NYSE:
ABT) announced today that it has received CE Mark (Conformite Europeene)
approval for a 2.25 mm version of its XIENCE(TM) V Everolimus Eluting
ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
WASHINGTON, DC OCTOBER 22, 2007 Late-breaking results from the ENDEAVOR IV trial, presented at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation, show that the Endeavor zotarolimus-eluting stent
met the trials primary endpoint, demonstrating a similar overall sa...